First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases July 3, 2018August 16, 2022
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia April 29, 2024April 29, 2024
FDA Approval to Commence Huntington’s Disease Clinical Trial Using Prana’s PBT2: Huntington Study Group appointed to coordinate the trial and start recruitment July 17, 2013August 16, 2022